Paclitaxel-carboplatin-gemcitabine (TCG) versus paclitaxel-carboplatin (TC) as first line treatment in women with ovarian cancer: A randomized phase III GCIG Intergroup study (AGO…
AK Stähle, C Jackisch, B Schmalfeldt, S Loibl, K Wollschläger, HJ Lück, U Canzler, A duBois · Geburtshilfe und Frauenheilkunde · 2006 · Heft 09
Bibliografische Angaben
Zusammenfassung
Aims: Ovarian cancer is still not curable in the majority of patients. Addition of non cross-resistant drugs to standard TC is a potential option for improvement of efficacy. G showed good activity in recurrent ovarian cancer. In phase II trials G cood be added to TC with manegeable toxicity. Therefore, a prospectively randomized phase III Intergroup study comparing TCG to standard TC was initiated within the GCIG network. Patients and Methods: Recruitment started in 8/02 until 04/04. Patients with epithelial ovarian cancer FIGO stages IC-IV were randomized within 6 weeks after primary surgery to either TC (T 17…
